| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | H3L |
| Uniprot No | Q6NXT2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-135aa |
| 氨基酸序列 | MARTKQTARKSTGGKAPRKQLATKAARKSTPSTCGVKPHRYRPGTVALREIRRYQKSTELLIRKLPFQRLVREIAQDFNTDLRFQSAAVGALQEASEAYLVGLLEDTNLCAIHAKRVTIMPKDIQLARRIRGERA |
| 预测分子量 | 15,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于H3L重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：
1. **文献名称**: "Immunogenicity of recombinant H3L protein in a murine model of vaccinia virus infection"
**作者**: Smith J, et al.
**摘要**: 研究通过大肠杆菌表达系统制备重组H3L蛋白，并在小鼠模型中评估其免疫原性。结果显示，H3L联合佐剂可诱导高水平中和抗体，显著降低病毒载量，提示其作为天花疫苗候选的潜力。
2. **文献名称**: "Structural characterization of the H3L protein from monkeypox virus and its cross-reactive antibody response"
**作者**: Zhang L, et al.
**摘要**: 通过冷冻电镜解析猴痘病毒H3L蛋白的构象表位，发现其与牛痘病毒H3L高度同源。实验证明，重组H3L蛋白免疫兔血清可交叉中和不同正痘病毒，为广谱疫苗设计提供依据。
3. **文献名称**: "Comparative evaluation of H3L and A27L recombinant proteins as subunit vaccines against orthopoxviruses"
**作者**: Gupta R, et al.
**摘要**: 比较H3L与A27L重组蛋白的免疫保护效果。在恒河猴攻毒实验中，H3L单独免疫组的中和抗体效价较A27L组更高，且联合使用两蛋白可协同增强T细胞应答。
4. **文献名称**: "High-yield production and purification of H3L extracellular enveloped virion antigen for serological diagnostics"
**作者**: Kim S, et al.
**摘要**: 开发昆虫细胞表达系统高效制备H3L重组蛋白，优化纯化工艺后应用于ELISA检测。临床样本验证显示，H3L抗原对天花疫苗接种者血清的检出灵敏度达98%。
注：以上为模拟内容，实际文献需通过学术数据库检索确认。若需真实文献，建议使用关键词“H3L recombinant protein vaccinia/monkeypox”在PubMed或Web of Science中查询。
The H3L recombinant protein is a key antigenic component derived from the vaccinia virus, a member of the Orthopoxvirus genus closely related to the variola virus responsible for smallpox. The H3L gene encodes a major envelope protein critical for viral morphogenesis and infectivity. This 37-40 kDa protein is highly conserved across orthopoxviruses, making it a strategic target for vaccine development and immunological studies.
Recombinant H3L is produced through genetic engineering, where the H3L gene is cloned and expressed in heterologous systems like Escherichia coli or mammalian cell cultures. This allows large-scale, safe production without handling live viruses. Structurally, H3L contains immunodominant epitopes that trigger robust neutralizing antibody responses, essential for protective immunity against poxvirus infections.
Research on H3L gained momentum post-smallpox eradication due to its potential in next-generation vaccines. Unlike traditional live vaccines, recombinant H3L-based subunit vaccines aim to reduce side effects while maintaining efficacy. It is also pivotal in diagnostic tools, enabling antibody detection in vaccinated or exposed individuals. Additionally, H3L serves as a model to study host-pathogen interactions, particularly viral entry mechanisms and immune evasion strategies.
Recent zoonotic outbreaks of monkeypox have reignited interest in H3L, as cross-reactive immunity between orthopoxviruses could inform pan-poxvirus countermeasures. Furthermore, its role in biodefense research underscores its importance in preparedness against potential smallpox re-emergence. Studies continue to explore adjuvants and delivery systems to enhance H3L’s immunogenicity, bridging gaps between experimental data and clinical applications. Overall, H3L recombinant protein remains a cornerstone in advancing poxvirus therapeutics, diagnostics, and fundamental virology.
×
